

Books, Chapters and Invited Reviews

Posner J. Pain models in healthy volunteers. The Role of Clinical Measurement in Evaluation of New Drugs. Publ. Woolf Edinburgh. Ed. Nimmo WS & Tucker G 1991; Chapter 8: 73-90.

Cohen AF, Posner J (Editors). A Guide to Clinical Research. Publ. Kluwer Academic Publishers Inc. 2nd edition 2000 (1st edition 1995).

Posner J, Rolan PE. The Textbook of Pharmaceutical Medicine. Chapter 5: Clinical Pharmacokinetics Publ. Ed. Griffin, O'Grady and Wells, 3rd edition 1998 and previous editions.

Posner J. The Textbook of Pharmaceutical Medicine. Chapter 4: Exploratory Development. Publ. Blackwells. Ed. Griffin, Publ. 6th edition 2009, and all previous editions.

Posner J. The Textbook of Pharmaceutical Medicine. Editor of 7th Edition with Griffin JP and G. Barker. Publ. Wiley. Author of Chapter 4 and Chapter 7. In Press.

Posner J. Clinical Pharmacology: The Basics. Surgery 2009; 27:153-157.

Posner J. Clinical Pharmacology: The Basics. Surgery 2012; 4:174-180.

Editorials, Letters, Commentaries and Invited Reviews

Cohen AF, Posner J. Effects of 2 antihistamine drugs on actual driving performance. Br Med J 1984; 288:935.

Posner J. Clinical pharmacology - mutual benefits from greater cooperation between academia and the pharmaceutical industry. Br J Clin Pharmacol 1991; 32:531-533.

Harry J, Baber N and Posner J. HIV screening in healthy volunteers. Br J Clin Pharmacol 1995; 39:213.

Posner J, Griffin JP. Commentary: Generic Prescribing. Br J Clin Pharmacol 2011; 72 (5):731-2.

Posner J. Commentary: Optimising the dose of dabigatran etexilate. Br J Clin Pharmacol 2012; in press. Published on line 7th June 2012. DOI: 10.1111/j.1365-2125.2012.04353.x

Abstracts

Author of more than 50 peer-reviewed abstracts of oral and poster presentations mostly published in the British Journal of Clinical Pharmacology and numerous other posters presented at international conferences and symposia.

The most recent poster was presented at the American Society of Clinical Oncology June 2012 entitled: A phase 1 study of S-222611, an oral reversible dual inhibitor of EGFR and HER2, in patients with solid tumors. Baird R, Papa S, Cresti N, Hatcher H, Hogarth L, Jamal-Hanjani M, Donaldson KM, Posner J, Kawabata I, Frenkel E, Jodrell D, Plummer R, Spicer J

Refereed Papers

1. Bennett A, Posner J. Studies on prostaglandin antagonists. Br J Pharmacol 1971; 42:584-594.
2. Posner J. Prostaglandin E₂ and the bovine sphincter pupillae. Br J Pharmacol 1973; 49:415-427.
3. Larson E, Nicholson C, Loewi G, Posner J, Tyrrell DAJ. Arthritis after meningococcal meningitis. Br Med J 1977; 1:618

Publications – John Posner BSc PhD MBBS FRCP FFPM

4. Berginer V, Posner J, Kahana E. Multiple Sclerosis in Israeli Bedouin. *Israel J Med Sci* 1982; 18:249-252.
5. Posner J, Ilya R, Wanderman K, Weitzmann S. Systolic Time Intervals in Diabetes. *Diabetologia* 1983; 24:249-252.
6. Weinhouse E, Kaplansky Y, Posner J. Comparison of digoxin-induced cardiac toxicity in resistant and sensitive species. *J Pharm Pharmacol* 1983; 35:580-583.
7. Posner J, Sobel RJ, Glick S. Effects of amiodarone on thyroid hormone economy. *Israel J Med Sci* 1984; 20:113-117.
8. Posner J. A modified submaximal effort tourniquet test for evaluation of analgesics. *Pain* 1984; 19:143-151.
9. Posner J, Bye A, Jeal S, Peck AW, Whiteman PD. Alcohol and pharmacokinetics of bupropion in healthy volunteers. *Europ J Clin Pharmacol* 1984; 26:627-630.
10. Cohen AF, Posner J, Ashby L, Smith R, Peck AW. A comparison of methods of assessing the sedative effects of diphenhydramine on skills related to car driving. *Europ J Clin Pharmacol* 1984; 27:471-475.
11. Whiteman PD, Bye A, Fowle ASE, Jeal S, Land G, Posner J. Tolerance and pharmacokinetics of an acyclovir analogue A515U in man. *Europ J Clin Pharmacol* 1984; 27:471-475.
12. Posner J, Telekes A, Crowley D, Phillipson R, Peck AW. Effects of an opiate on cold-induced pain and the CNS in healthy volunteers. *Pain* 1985; 23: 73-82.
13. Posner J, Bye A, Dean K, Peck AW, Whiteman PD. The disposition of bupropion and its metabolites in healthy male volunteers after single and multiple doses. *Europ J Clin Pharmacol* 1985; 29: 97-103.
14. Posner J, Burke CA. The effects of naloxone on opiate and placebo analgesia in healthy volunteers. *Psychopharmacol* 1985; 87:468-473.
15. Findlay JWA, Fowle ASE, Butz RF, Jones EC, Weatherley BC, Welch RM, Posner J. Comparative disposition of codeine and pholcodine in man after single oral doses. *Br J Clin Pharmac* 1986; 22:61-71.
16. Posner J, Danhof M, Theunissen MWE, Breimer DD, Whiteman PD. The disposition of antipyrine and its metabolites in young and elderly healthy volunteers. *Br J Clin Pharmac* 1987; 24:51-55.
17. Posner J, Dean K, Jeal S, Moody SG, Peck AW, Rutter G, Telekes A. A preliminary study of the pharmacodynamincs and pharmacokinetics of a novel enkephalin analogue [Tyr.D.Arg-Gly-Phe(4NO₂).Pro.NH₂(BW443C)] in healthy volunteers. *Europ J Clin Pharmacol* 1988; 34:67-71.
18. Posner J, Cohen AF, Land G, Winton C, Peck AW. The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinemia (Gilbert's Syndrome). *Br J Clin Pharmac* 1989; 28:117-120.
19. Rolan PE, Adams J, Posner J. Histamine bronchial challenge in volunteers. *J Int Med Res* 1989; 17 (Suppl 2): 35-39B.
20. Posner J, Moody SG, Peck AW, Rutter D, Telekes A. Analgesic, central, cardiovascular and endocrine effects of the enkephalin analogue Tyr-D.Arg-Cly-Phe(4NO₂)-Pro-NH₂ (443C81) in healthy volunteers. *Europ J Clin Pharmacol* 1990; 38:213-218.
21. Rolan PE, Phillips S, Adams J, Posner J. The onset of effect of the H₁-antagonist acrivastine ("Semprex") assessed by histamine bronchial challenge in volunteers. *Europ J Clin Pharmacol* 1990; 39:311-313.

Publications – John Posner BSc PhD MBBS FRCP FFPM

22. Cohen AF, Harkin N, Posner J. The cardiovascular effects of a novel enkephalin analogue, 443C81, in man. *J Cardiovas Pharmacol* 1990; 16:455-460.
23. Posner J, Holdich T, Crome P. Comparison of lamotrigine pharmacokinetics in young and elderly healthy volunteers. *J Pharmaceut Med* 1991;1: 121-128.
24. Chowdry NB, Gray SJ, Posner J, Fuller RW. The effect of 443C81, a opioid receptor agonist, on the response to inhaled capsaicin in healthy volunteers. *Br J Clin Pharmac* 1991; 32: 633-636.
25. Gray SJ, Parker JE, Giles H, Bolofo M, Phillips S, Posner J. The effects of a partial PGD₂ agonist, 192C, on platelet aggregation and the cardiovascular system in healthy volunteers. *Br J Clin Pharmac* 1992; 34:344-351.
26. Phillips SC, Rolan PE, Posner J, Malpern S, Wijayawardhana P, Crome P. Greater ease of swallowing of a new film coated 800 mg dispersible acyclovir (Zovirax) tablet compared to the standard 800 mg tablet in healthy elderly volunteers. *J Pharm Med* 1992; 2:259-262.
27. Rolan PE, Parker JE, Gray SJ, Weatherley BC, Ingram J, Leavens W, Wootton R, Posner J. The pharmacokinetics, tolerability and pharmacodynamics of tucaresol (589C80:4)[2-formyl-3-hydroxyphenoxymethyl], a potential anti-sickling agent, following oral administration to healthy subjects. *Br J Clin Pharmac* 1993; 35:419-425.
28. Rolan PE, Mercer AJ, Weatherley BC, Holdich T, Meire H, Peck RW, Ridout G, Posner J. Examination of some factors responsible for a food-induced increase in the absorption of atovaquone. *Br J Clin Pharmac* 1994; 37:13-20.
29. Peck RW, Wootton R, Lee DR, Jackson SHD, Posner J. The bioavailability and disposition of 1-β-D-arabinofuranosyl)-5-(1-propynyl)uracil (882C87), a potent, new anti-varicella zoster virus agent. *Br J Clin Pharmac* 1995; 39:143-149.
30. Peck RW, Weatherley BC, Wootton R, Crome P, Holdich TA, Posner J. Pharmacokinetics and tolerability of single oral doses of 882C87, a potent new anti-varicella zoster virus agent, in healthy volunteers. *Antimicrobial Agents and Chemotherapy* 1995; 39:20-27.
31. Rolan PE, Mercer A, Wootton R, Posner J. Pharmacokinetics and pharmacodynamics of tucaresol, an antisickling agent, in healthy volunteers. *Br J Clin Pharmac* 1995; 39:375-380.
32. Soul-Lawton J, Seaber E, On N, Wootton R, Rolan P, Posner J. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. *Antimicrobial agents and Chemotherapy* 1995; 39:2759-2764.
33. Peck R, Wiggs R, Posner J. The tolerability, pharmacokinetics and lack of effect on plasma cholesterol of 447C88, an AcylCoA:Cholesterol Acyl Transferase (ACAT) inhibitor with low bioavailability in healthy volunteers. *Europ J Clin Pharmacol.* 1995; 49:243-249.
34. Mercer A, Hussein Z, Lamb R, Hobbiger S, Posner J. The pharmacokinetics and pharmacodynamics of increasing intravenous doses of 619C89, a novel compound for the acute treatment of stroke, in healthy volunteers. *Ann NY Acad Sci.* 1995; 765:324-327.
35. Peck RW, Wiggs R, Callaghan J, Wootton R, Crome P, Fraser I, Frick L, Posner J. Inhibition of dihydropyrimidine dehydrogenase by 5-propynyluracil, a metabolite of the antiviral zoster virus agent, netivudine. *Clin Pharmacol Therap* 1996; 59: 22-31.
36. Seaber E, On N, Phillips S, Churchus R, Posner J, Rolan PE. The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers. *Br J Clin Pharmac* 1996; 41:141-148.
37. De Bony F, Bidault R, Peck R, Posner J. Lack of interaction between valaciclovir, the L-valyl ester of acyclovir, and Maalox antacid. *J Antimicrob Chemotherap* 1996; 37:383-387.

Publications – John Posner BSc PhD MBBS FRCP FFPM

38. Fillastre JP, Godin M, Legallicier B, Chretien P, Bidault R, Gilotin C, Wootton R, Posner J, Peck RW. Pharmacokinetics of netivudine, a potent antiviral zoster virus drug, in patients with renal impairment. *J Antimicrob Chemother* 1996; 37:965-974.
39. Le Roy F, Godin M, Legallicier B, Fillastre JP, Bidault R, Posner J, Peck RW. Pharmacokinetics of netivudine in haemodialysis patients. *J Antimicrob Chemother* 1996;38:913-915.
40. Hussein Z, Fraser IJ, Lees KR, Muir KW, Lunnon MW, Hobbiger SF, Posner J. Pharmacokinetics of 619C89, a novel neuronal sodium channel inhibitor, in acute stroke patients after loading and discrete maintenance infusions. *Br J Clin Pharmacol* 1996; 41:505-513.
41. Arya R, Rolan PE, Wootton R, Posner J, Bellingham AJ. Tucaresol increases oxygen affinity and reduces hemolysis in subjects with sickle cell anaemia. *Br J Haematol* 1996; 93:817-821.
42. Davis JD, Dixon R, Khan AZ, Toon S, Rolan PE, Posner J. Atovaquone has no effect on the pharmacokinetics of phenytoin in healthy male volunteers. *Br J Clin Pharmacol* 1996; 42:246-248.
43. Dixon R, Pozniak AL, Watt HM, Rolan P, Posner J. Single-dose and steady-state pharmacokinetics of a novel microfluidized suspension of atovaquone in human immunodeficiency virus-seropositive patients. *Antimicrob Agents Chemother* 1996; 40:556-560.
44. Wootton R, Soul-Lawton J, Rolan PE, Fook Sheung CTC, Cooper JDH, Posner J. Comparison of the pharmacokinetics of lamotrigine in patients with chronic renal failure and healthy volunteers. *Br J Clin Pharmacol* 1997; 43:23-27.
45. Hussein Z, Posner J. Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: a retrospective analysis of routine monitoring data. *Br J Clin Pharmacol* 1997; 43:457-465.
46. Dixon R, Gillotin C, Gibbens M, Posner J, Peck RW. The pharmacokinetics and effects on blood pressure of multiple doses of the novel anti-migraine drug zolmitriptan (311C90) in healthy volunteers. *Br J Clin Pharmacol* 1997; 43:273-281.
47. Seaber E, On N, Dixon RM, Gibbens M, Leavens WJ, Liptrot J, Chittick G, Posner J, Rolan PE, Peck RW. The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90). *Br J Clin Pharmacol* 1997; 43:579-587.
48. Dixon RM, Meire HB, Posner J, Rolan PE. Evaluation of non-invasive techniques to assess vasoconstriction in healthy volunteers using methoxamine as a probe drug. *Cephalgia* 1997; 17:639-646.
49. Rolan PE, Mercer AJ, Tate E, Benjamin I, Posner J. Disposition of atovaquone in humans. *Antimicrob Agents Chemother* 1997; 41:1319-1321.
50. Seaber EJ, Ridout G, Layton G, Posner J, Peck RW. The novel anti-migraine compound zolmitriptan (Zomig 311C90) has not clinically significant interactions with paracetamol or metoclopramide. *Eur J Clin Pharmacol* 1997; 53:229-234.
51. Peck RW, Seaber EJ, Dixon R, Gillotin CG, Weatherley BC, Layton G, Posner J. The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90). *Br J Clin Pharmacol* 1997; 44:595-599.
52. Dixon, RM, Meire HB, Evans DH, Watt H, On N, Posner J, Rolan PE. Peripheral vascular effects and pharmacokinetics of the antimigraine compound, zolmitriptan, in combination with ergotamine in healthy volunteers. *Cephalgia* 1997; 17:639-646.
53. Peck RW, Seaber EJ, Dixon RM, Layton GR, Weatherley BC, Jackson SHD, Rolan PE, Posner J. The pharmacodynamics and pharmacokinetics of the 5HT_{1B/D} - agonist zolmitriptan in healthy young and elderly men and women. *Clin Pharmacol Ther* 1998; 63:342-353.
54. Soul-Lawton JH, Weatherley BC, Posner J, Layton G, Peck RW. Lack of interaction between valaciclovir, the L-valyl ester of aciclovir and digoxin. *Br J Clin Pharmacol* 1998; 45:87-89.

Publications – John Posner BSc PhD MBBS FRCP FFPM

55. Mercer AJ, Lamb RJ, Rolan, PE, Gibbens M, Posner J. Lack of an effect of zolmitriptan (Zomig, 311C90), on psychometric task performance: results of a placebo controlled study in healthy volunteers. *Psychopharmacology* 1998; 140:398-404.
56. Peck RW, Wooton R, Wiggs R, Layton G, Posner J. Effect of food and gender on the pharmacokinetics of tucaresol in healthy volunteers. *Br J Clin Pharmac* 1998; 46:83-86.
57. Klamt JG, Posner J. Effects of lamotrigine on pain-induced chemo-somatosensory evoked potentials. *Anaesthesia* 1999; 54:774-777.
58. De Bony F, Tod M, Bidault R, On NT, Posner J, Rolan P. Multiple interactions of cimetidine and probenecid with valaciclovir and its metabolite acyclovir. *Antimicrob Agents Chemother* 2002; 46:458-63.
59. Calder N, Boyce M, Posner J, Sciberras D. Clinical pharmacology studies in UK Phase I units: an AHPPI survey 1999-2000. *Br J Clin Pharmac* 2004; 57:76-79.
60. Rave, K, Nosek L, Posner J, Heise T, Roggen K, Hoogdalem EJ. Renal glucose excretion as a function of blood glucose concentration in subjects with type 2 diabetes-results of a hyperglycaemic glucose clamp study. *Nephrol Dial Transplant*. 2006; 21:2166-71.